{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,24]],"date-time":"2026-10-24T23:22:01Z","timestamp":1792884121838,"version":"4.5.0"},"reference-count":65,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,7,31]],"date-time":"2026-07-31T00:00:00Z","timestamp":1785456000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,9,17]],"date-time":"2026-09-17T00:00:00Z","timestamp":1789603200000},"content-version":"vor","delay-in-days":48,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"name":"Mayo Clinic Center for Regenerative Biotherapeutics","id":[{"id":"https:\/\/ror.org\/02qp3tb03","id-type":"ROR","asserted-by":"crossref"}]},{"name":"Mayo Clinic Comprehensive Cancer Center"},{"name":"National Institutes of Health"},{"name":"Department of Defense"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Mol Cancer"],"DOI":"10.1186\/s12943-026-02744-0","type":"journal-article","created":{"date-parts":[[2026,7,31]],"date-time":"2026-07-31T05:24:58Z","timestamp":1785475498000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Redifferentiation-enabled TSHRCART cells overcome antigen loss in aggressive thyroid cancers"],"prefix":"10.1186","volume":"25","author":[{"given":"Claudia","family":"Manriquez-Roman","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elizabeth L.","family":"Siegler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Justyna J.","family":"Gleba","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Truc N.","family":"Huynh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Grace E.","family":"DeFranco","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aylin Alasonyalilar","family":"Demirer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matthew L.","family":"Pawlush","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Redig","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Skyeler M.","family":"Klinge","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Long K.","family":"Mai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"James L.","family":"Miller","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Erin E.","family":"Miller","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brooke L.","family":"Kimball","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Erin E.","family":"Tapper","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"R. Leo","family":"Sakemura","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carli M.","family":"Stewart","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ismail","family":"Can","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Olivia L.","family":"Sirpilla","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jennifer M.","family":"Feigin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kun","family":"Yun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Omar L.","family":"Gutierrez-Ruiz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hong","family":"Xia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mehrdad","family":"Hefazi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kendall J.","family":"Schick","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ekene J.","family":"Ogbodo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gloria","family":"Olivier","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yushi","family":"Qiu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert C.","family":"Smallridge","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Abba","family":"Zubair","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Han W.","family":"Tun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John A.","family":"Copland","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Saad S.","family":"Kenderian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,7,31]]},"reference":[{"key":"2744_CR1","doi-asserted-by":"publisher","first-page":"803","DOI":"10.1038\/s41422-025-01180-x","volume":"35","author":"X Li","year":"2025","unstructured":"Li X, et al. Lineage plasticity and histological transformation: tumor histology as a spectrum. Cell Res. 2025;35:803\u201323. https:\/\/doi.org\/10.1038\/s41422-025-01180-x.","journal-title":"Cell Res"},{"key":"2744_CR2","doi-asserted-by":"publisher","first-page":"3019","DOI":"10.7150\/ijbs.72534","volume":"18","author":"A Zhang","year":"2022","unstructured":"Zhang A, Miao K, Sun H, Deng CX. Tumor heterogeneity reshapes the tumor microenvironment to influence drug resistance. Int J Biol Sci. 2022;18:3019\u201333. https:\/\/doi.org\/10.7150\/ijbs.72534.","journal-title":"Int J Biol Sci"},{"key":"2744_CR3","doi-asserted-by":"publisher","first-page":"479","DOI":"10.1007\/s11912-023-01380-x","volume":"25","author":"G Guzman","year":"2023","unstructured":"Guzman G, Reed MR, Bielamowicz K, Koss B, Rodriguez A. CAR-T therapies in solid tumors: opportunities and challenges. Curr Oncol Rep. 2023;25:479\u201389. https:\/\/doi.org\/10.1007\/s11912-023-01380-x.","journal-title":"Curr Oncol Rep"},{"key":"2744_CR4","doi-asserted-by":"publisher","first-page":"1219","DOI":"10.1158\/2159-8290.CD-18-0442","volume":"8","author":"RG Majzner","year":"2018","unstructured":"Majzner RG, Mackall CL. Tumor antigen escape from CAR T-cell therapy. Cancer Discov. 2018;8:1219\u201326. https:\/\/doi.org\/10.1158\/2159-8290.CD-18-0442.","journal-title":"Cancer Discov"},{"key":"2744_CR5","doi-asserted-by":"publisher","DOI":"10.1093\/jimmun\/vkaf047","author":"CM Stewart","year":"2025","unstructured":"Stewart CM, Siegler EL, Kenderian SS. The road ahead for chimeric antigen receptor T cells. J Immunol. 2025. https:\/\/doi.org\/10.1093\/jimmun\/vkaf047.","journal-title":"J Immunol"},{"key":"2744_CR6","doi-asserted-by":"publisher","first-page":"2524","DOI":"10.1182\/blood.V126.23.2524.2524","volume":"126","author":"E Jacoby","year":"2015","unstructured":"Jacoby E, et al. Lineage switch as a relapse mechanism of pre-B acute lymphoblastic leukemia following CD19 CAR. Blood. 2015;126:2524\u20132524. https:\/\/doi.org\/10.1182\/blood.V126.23.2524.2524.","journal-title":"Blood"},{"key":"2744_CR7","doi-asserted-by":"publisher","DOI":"10.4161\/21624011.2014.970027","volume":"3","author":"GL Beatty","year":"2014","unstructured":"Beatty GL, Moon EK. Chimeric antigen receptor T cells are vulnerable to immunosuppressive mechanisms present within the tumor microenvironment. Oncoimmunology. 2014;3:e970027. https:\/\/doi.org\/10.4161\/21624011.2014.970027.","journal-title":"Oncoimmunology"},{"key":"2744_CR8","doi-asserted-by":"publisher","first-page":"165","DOI":"10.1038\/s41434-018-0007-x","volume":"25","author":"M Castellarin","year":"2018","unstructured":"Castellarin M, Watanabe K, June CH, Kloss CC, Posey AD. Driving cars to the clinic for solid tumors. Gene Ther. 2018;25:165\u201375. https:\/\/doi.org\/10.1038\/s41434-018-0007-x.","journal-title":"Gene Ther"},{"key":"2744_CR9","doi-asserted-by":"publisher","first-page":"2548","DOI":"10.7150\/ijbs.34213","volume":"15","author":"S Ma","year":"2019","unstructured":"Ma S, et al. Current progress in CAR-T cell therapy for solid tumors. Int J Biol Sci. 2019;15:2548\u201360. https:\/\/doi.org\/10.7150\/ijbs.34213.","journal-title":"Int J Biol Sci"},{"key":"2744_CR10","doi-asserted-by":"publisher","first-page":"269","DOI":"10.1007\/s40778-017-0101-9","volume":"3","author":"B Moghimi","year":"2017","unstructured":"Moghimi B, Barrett D. CAR T cells for solid tumors. Curr Stem Cell Rep. 2017;3:269\u201378. https:\/\/doi.org\/10.1007\/s40778-017-0101-9.","journal-title":"Curr Stem Cell Rep"},{"key":"2744_CR11","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1038\/s41408-021-00459-7","volume":"11","author":"RC Sterner","year":"2021","unstructured":"Sterner RC, Sterner RM. CAR-T cell therapy: current limitations and potential strategies. 2021;11:69. https:\/\/doi.org\/10.1038\/s41408-021-00459-7.","journal-title":"CAR-T cell therapy: current limitations and potential strategies"},{"key":"2744_CR12","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1016\/j.omto.2022.03.009","volume":"25","author":"LA Kankeu Fonkoua","year":"2022","unstructured":"Kankeu Fonkoua LA, Sirpilla O, Sakemura R, Siegler EL, Kenderian SS. CAR T cell therapy and the tumor microenvironment: current challenges and opportunities. Mol Ther Oncolytics. 2022;25:69\u201377. https:\/\/doi.org\/10.1016\/j.omto.2022.03.009.","journal-title":"Mol Ther Oncolytics"},{"key":"2744_CR13","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.exphem.2022.02.001","volume":"108","author":"I Can","year":"2022","unstructured":"Can I, Cox MJ, Siegler EL, Sakemura R, Kenderian SS. Challenges of chimeric antigen receptor T-cell therapy in chronic lymphocytic leukemia: lessons learned. Exp Hematol. 2022;108:1\u20137. https:\/\/doi.org\/10.1016\/j.exphem.2022.02.001.","journal-title":"Exp Hematol"},{"key":"2744_CR14","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2021012811","author":"R Sakemura","year":"2022","unstructured":"Sakemura R, et al. Targeting cancer-associated fibroblasts in the bone marrow prevents resistance to CART-cell therapy in multiple myeloma. Blood. 2022. https:\/\/doi.org\/10.1182\/blood.2021012811.","journal-title":"Blood"},{"key":"2744_CR15","doi-asserted-by":"publisher","first-page":"681","DOI":"10.1182\/blood.V126.23.681.681","volume":"126","author":"SA Grupp","year":"2015","unstructured":"Grupp SA, et al. Durable remissions in children with relapsed\/refractory ALL treated with T cells engineered with a CD19-targeted chimeric antigen receptor (CTL019). Blood. 2015;126:681\u2013681.","journal-title":"Blood"},{"key":"2744_CR16","doi-asserted-by":"publisher","first-page":"2189","DOI":"10.1016\/j.ymthe.2017.06.008","volume":"25","author":"AJ Walker","year":"2017","unstructured":"Walker AJ, et al. Tumor antigen and receptor densities regulate efficacy of a chimeric antigen receptor targeting anaplastic lymphoma kinase. Mol Ther. 2017;25:2189\u2013201. https:\/\/doi.org\/10.1016\/j.ymthe.2017.06.008.","journal-title":"Mol Ther"},{"key":"2744_CR17","doi-asserted-by":"publisher","first-page":"112","DOI":"10.1038\/s41586-019-1054-1","volume":"568","author":"M Hamieh","year":"2019","unstructured":"Hamieh M, et al. CAR T cell trogocytosis and cooperative killing regulate tumour antigen escape. Nature. 2019;568:112\u20136. https:\/\/doi.org\/10.1038\/s41586-019-1054-1.","journal-title":"Nature"},{"key":"2744_CR18","doi-asserted-by":"publisher","first-page":"917","DOI":"10.2967\/jnumed.118.216721","volume":"60","author":"O ElMokh","year":"2019","unstructured":"ElMokh O, et al. MEK inhibition induces therapeutic iodine uptake in a murine model of anaplastic thyroid cancer. J Nucl Med. 2019;60:917\u201323. https:\/\/doi.org\/10.2967\/jnumed.118.216721.","journal-title":"J Nucl Med"},{"key":"2744_CR19","doi-asserted-by":"publisher","first-page":"1341","DOI":"10.1158\/1078-0432.CCR-06-1753","volume":"13","author":"D Liu","year":"2007","unstructured":"Liu D, et al. Suppression of BRAF\/MEK\/MAP kinase pathway restores expression of iodide-metabolizing genes in thyroid cells expressing the V600E BRAF mutant. Clin Cancer Res. 2007;13:1341\u20139. https:\/\/doi.org\/10.1158\/1078-0432.CCR-06-1753.","journal-title":"Clin Cancer Res"},{"key":"2744_CR20","doi-asserted-by":"publisher","first-page":"623","DOI":"10.1056\/NEJMoa1209288","volume":"368","author":"AL Ho","year":"2013","unstructured":"Ho AL, et al. Selumetinib-enhanced radioiodine uptake in advanced thyroid cancer. N Engl J Med. 2013;368:623\u201332. https:\/\/doi.org\/10.1056\/NEJMoa1209288.","journal-title":"N Engl J Med"},{"key":"2744_CR21","doi-asserted-by":"publisher","first-page":"2056","DOI":"10.1158\/1078-0432.CCR-11-0563","volume":"18","author":"DN Hayes","year":"2012","unstructured":"Hayes DN, et al. Phase II efficacy and pharmacogenomic study of Selumetinib (AZD6244; ARRY-142886) in iodine-131 refractory papillary thyroid carcinoma with or without follicular elements. Clin Cancer Res. 2012;18:2056\u201365. https:\/\/doi.org\/10.1158\/1078-0432.CCR-11-0563.","journal-title":"Clin Cancer Res"},{"key":"2744_CR22","doi-asserted-by":"publisher","first-page":"87","DOI":"10.4274\/2017.26.suppl.10","volume":"26","author":"M Tuncel","year":"2017","unstructured":"Tuncel M. Thyroid stimulating hormone receptor. Mol Imaging Radionucl Ther. 2017;26:87\u201391. https:\/\/doi.org\/10.4274\/2017.26.suppl.10.","journal-title":"Mol Imaging Radionucl Ther"},{"key":"2744_CR23","doi-asserted-by":"publisher","first-page":"R191","DOI":"10.1530\/ERC-17-0010","volume":"24","author":"CW Rowe","year":"2017","unstructured":"Rowe CW, et al. Targeting the TSH receptor in thyroid cancer. Endocr Relat Cancer. 2017;24:R191\u2013202. https:\/\/doi.org\/10.1530\/ERC-17-0010.","journal-title":"Endocr Relat Cancer"},{"key":"2744_CR24","doi-asserted-by":"publisher","first-page":"915","DOI":"10.1210\/jcem-51-4-915","volume":"51","author":"P Carayon","year":"1980","unstructured":"Carayon P, Thomas-Morvan C, Castanas E, Tubiana M. Human thyroid cancer: membrane thyrotropin binding and adenylate cyclase activity. J Clin Endocrinol Metab. 1980;51:915\u201320. https:\/\/doi.org\/10.1210\/jcem-51-4-915.","journal-title":"J Clin Endocrinol Metab"},{"key":"2744_CR25","doi-asserted-by":"publisher","first-page":"3169","DOI":"10.1210\/jc.2017-01845","volume":"103","author":"LA Marlow","year":"2018","unstructured":"Marlow LA, et al. Methodology, criteria, and characterization of patient-matched thyroid cell lines and patient-derived tumor xenografts. J Clin Endocrinol Metab. 2018;103:3169\u201382. https:\/\/doi.org\/10.1210\/jc.2017-01845.","journal-title":"J Clin Endocrinol Metab"},{"key":"2744_CR26","doi-asserted-by":"publisher","first-page":"475","DOI":"10.1089\/thy.1998.8.475","volume":"8","author":"A Zielke","year":"1998","unstructured":"Zielke A, et al. Establishment of a highly differentiated thyroid cancer cell line of Hurthle cell origin. Thyroid. 1998;8:475\u201383. https:\/\/doi.org\/10.1089\/thy.1998.8.475.","journal-title":"Thyroid"},{"key":"2744_CR27","doi-asserted-by":"publisher","first-page":"697","DOI":"10.1182\/blood-2018-10-881722","volume":"133","author":"RM Sterner","year":"2019","unstructured":"Sterner RM, et al. GM-CSF inhibition reduces cytokine release syndrome and neuroinflammation but enhances CAR-T cell function in xenografts. Blood. 2019;133:697\u2013709. https:\/\/doi.org\/10.1182\/blood-2018-10-881722.","journal-title":"Blood"},{"key":"2744_CR28","doi-asserted-by":"publisher","first-page":"2083","DOI":"10.1111\/j.1537-2995.2006.01033.x","volume":"46","author":"AB Dietz","year":"2006","unstructured":"Dietz AB, et al. A novel source of viable peripheral blood mononuclear cells from leukoreduction system chambers. Transfusion. 2006;46:2083\u20139. https:\/\/doi.org\/10.1111\/j.1537-2995.2006.01033.x.","journal-title":"Transfusion"},{"key":"2744_CR29","doi-asserted-by":"publisher","first-page":"393","DOI":"10.1016\/B978-0-12-381296-4.00022-1","volume":"485","author":"J Sanders","year":"2010","unstructured":"Sanders J, Miguel RN, Furmaniak J, Smith BR. TSH receptor monoclonal antibodies with agonist, antagonist, and inverse agonist activities. Methods Enzymol. 2010;485:393\u2013420. https:\/\/doi.org\/10.1016\/B978-0-12-381296-4.00022-1.","journal-title":"Methods Enzymol"},{"key":"2744_CR30","doi-asserted-by":"publisher","first-page":"1222","DOI":"10.1158\/2326-6066.CIR-22-0254","volume":"11","author":"RL Sakemura","year":"2023","unstructured":"Sakemura RL, et al. AXL inhibition improves the antitumor activity of chimeric antigen receptor T cells. Cancer Immunol Res. 2023;11:1222\u201336. https:\/\/doi.org\/10.1158\/2326-6066.CIR-22-0254.","journal-title":"Cancer Immunol Res"},{"key":"2744_CR31","doi-asserted-by":"publisher","DOI":"10.1038\/s41375-022-01572-7","author":"MJ Cox","year":"2022","unstructured":"Cox MJ, et al. GM-CSF disruption in CART cells modulates T cell activation and enhances CART cell anti-tumor activity. Leukemia. 2022. https:\/\/doi.org\/10.1038\/s41375-022-01572-7.","journal-title":"Leukemia"},{"key":"2744_CR32","doi-asserted-by":"publisher","first-page":"1529","DOI":"10.1016\/j.ymthe.2020.12.033","volume":"29","author":"MJ Cox","year":"2021","unstructured":"Cox MJ, et al. Leukemic extracellular vesicles induce chimeric antigen receptor T cell dysfunction in chronic lymphocytic leukemia. Mol Ther. 2021;29:1529\u201340. https:\/\/doi.org\/10.1016\/j.ymthe.2020.12.033.","journal-title":"Mol Ther"},{"key":"2744_CR33","doi-asserted-by":"publisher","first-page":"1035","DOI":"10.1158\/2326-6066.CIR-20-0901","volume":"9","author":"R Sakemura","year":"2021","unstructured":"Sakemura R, et al. Development of a clinically relevant reporter for chimeric antigen receptor T-cell expansion, trafficking, and toxicity. Cancer Immunol Res. 2021;9:1035\u201346. https:\/\/doi.org\/10.1158\/2326-6066.CIR-20-0901.","journal-title":"Cancer Immunol Res"},{"key":"2744_CR34","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-024-51978-3","volume":"15","author":"CM Stewart","year":"2024","unstructured":"Stewart CM, et al. IL-4 drives exhaustion of CD8(+) CART cells. Nat Commun. 2024;15:7921. https:\/\/doi.org\/10.1038\/s41467-024-51978-3.","journal-title":"Nat Commun"},{"key":"2744_CR35","doi-asserted-by":"publisher","DOI":"10.1126\/science.1260419","volume":"347","author":"M Uhlen","year":"2015","unstructured":"Uhlen M, et al. Proteomics. Tissue-based map of the human proteome. Science. 2015;347:1260419. https:\/\/doi.org\/10.1126\/science.1260419.","journal-title":"Science"},{"key":"2744_CR36","doi-asserted-by":"publisher","first-page":"8113","DOI":"10.1158\/0008-5472.Can-06-4026","volume":"67","author":"WC van Staveren","year":"2007","unstructured":"van Staveren WC, et al. Human thyroid tumor cell lines derived from different tumor types present a common dedifferentiated phenotype. Cancer Res. 2007;67:8113\u201320. https:\/\/doi.org\/10.1158\/0008-5472.Can-06-4026.","journal-title":"Cancer Res"},{"key":"2744_CR37","doi-asserted-by":"publisher","first-page":"1333","DOI":"10.1089\/thy.2009.0195","volume":"19","author":"T Pilli","year":"2009","unstructured":"Pilli T, Prasad KV, Jayarama S, Pacini F, Prabhakar BS. Potential utility and limitations of thyroid cancer cell lines as models for studying thyroid cancer. Thyroid. 2009;19:1333\u201342. https:\/\/doi.org\/10.1089\/thy.2009.0195.","journal-title":"Thyroid"},{"key":"2744_CR38","doi-asserted-by":"publisher","first-page":"1110","DOI":"10.1210\/clinem\/dgab819","volume":"107","author":"H Li","year":"2022","unstructured":"Li H, et al. CAR-T cells targeting TSHR demonstrate safety and potent preclinical activity against differentiated thyroid cancer. J Clin Endocrinol Metab. 2022;107:1110\u201326. https:\/\/doi.org\/10.1210\/clinem\/dgab819.","journal-title":"J Clin Endocrinol Metab"},{"key":"2744_CR39","doi-asserted-by":"publisher","first-page":"707","DOI":"10.1089\/thy.2007.0097","volume":"17","author":"AM Meireles","year":"2007","unstructured":"Meireles AM, et al. Molecular and genotypic characterization of human thyroid follicular cell carcinoma-derived cell lines. Thyroid. 2007;17:707\u201315. https:\/\/doi.org\/10.1089\/thy.2007.0097.","journal-title":"Thyroid"},{"key":"2744_CR40","doi-asserted-by":"publisher","first-page":"6873","DOI":"10.2147\/OTT.S119980","volume":"9","author":"S Ahmadi","year":"2016","unstructured":"Ahmadi S, Stang M, Jiang XS, Sosa JA. Hurthle cell carcinoma: current perspectives. Onco Targets Ther. 2016;9:6873\u201384. https:\/\/doi.org\/10.2147\/OTT.S119980.","journal-title":"Onco Targets Ther"},{"key":"2744_CR41","doi-asserted-by":"publisher","unstructured":"McFadden, D. G. & Sadow, P. M. Genetics, Diagnosis, and Management of Hurthle Cell Thyroid Neoplasms. Front Endocrinol (Lausanne) 12, 696386 (2021). https:\/\/doi.org\/10.3389\/fendo.2021.696386","DOI":"10.3389\/fendo.2021.696386"},{"key":"2744_CR42","doi-asserted-by":"publisher","first-page":"3141","DOI":"10.1158\/1078-0432.CCR-18-2953","volume":"25","author":"I Landa","year":"2019","unstructured":"Landa I, et al. Comprehensive genetic characterization of human thyroid cancer cell lines: a validated panel for preclinical studies. Clin Cancer Res. 2019;25:3141\u201351. https:\/\/doi.org\/10.1158\/1078-0432.CCR-18-2953.","journal-title":"Clin Cancer Res"},{"key":"2744_CR43","doi-asserted-by":"publisher","first-page":"4885","DOI":"10.1158\/0008-5472.CAN-09-0727","volume":"69","author":"JC Ricarte-Filho","year":"2009","unstructured":"Ricarte-Filho JC, et al. Mutational profile of advanced primary and metastatic radioactive iodine-refractory thyroid cancers reveals distinct pathogenetic roles for BRAF, PIK3CA, and AKT1. Cancer Res. 2009;69:4885\u201393. https:\/\/doi.org\/10.1158\/0008-5472.CAN-09-0727.","journal-title":"Cancer Res"},{"key":"2744_CR44","doi-asserted-by":"publisher","first-page":"296","DOI":"10.1016\/j.ceb.2009.01.013","volume":"21","author":"JA Knauf","year":"2009","unstructured":"Knauf JA, Fagin JA. Role of MAPK pathway oncoproteins in thyroid cancer pathogenesis and as drug targets. Curr Opin Cell Biol. 2009;21:296\u2013303. https:\/\/doi.org\/10.1016\/j.ceb.2009.01.013.","journal-title":"Curr Opin Cell Biol"},{"key":"2744_CR45","doi-asserted-by":"publisher","first-page":"165","DOI":"10.1038\/s41434-018-0007-x","volume":"25","author":"M Castellarin","year":"2018","unstructured":"Castellarin M, Watanabe K, June CH, Kloss CC, Posey AD Jr. Driving cars to the clinic for solid tumors. Gene Ther. 2018;25:165\u201375. https:\/\/doi.org\/10.1038\/s41434-018-0007-x.","journal-title":"Gene Ther"},{"key":"2744_CR46","doi-asserted-by":"publisher","first-page":"2307","DOI":"10.1056\/NEJMc1613118","volume":"375","author":"JA Fagin","year":"2016","unstructured":"Fagin JA, Wells SA Jr. Biologic and Clinical Perspectives on Thyroid Cancer. N Engl J Med. 2016;375:2307. https:\/\/doi.org\/10.1056\/NEJMc1613118.","journal-title":"N Engl J Med"},{"key":"2744_CR47","doi-asserted-by":"publisher","first-page":"4107","DOI":"10.1210\/jc.2009-0662","volume":"94","author":"N Jin","year":"2009","unstructured":"Jin N, Jiang T, Rosen DM, Nelkin BD, Ball DW. Dual inhibition of mitogen-activated protein kinase kinase and mammalian target of rapamycin in differentiated and anaplastic thyroid cancer. J Clin Endocrinol Metab. 2009;94:4107\u201312. https:\/\/doi.org\/10.1210\/jc.2009-0662.","journal-title":"J Clin Endocrinol Metab"},{"key":"2744_CR48","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1200\/JCO.2017.73.6785","volume":"36","author":"V Subbiah","year":"2018","unstructured":"Subbiah V, et al. Dabrafenib and trametinib treatment in patients with locally advanced or metastatic BRAF V600-mutant anaplastic thyroid cancer. J Clin Oncol. 2018;36:7\u201313. https:\/\/doi.org\/10.1200\/JCO.2017.73.6785.","journal-title":"J Clin Oncol"},{"key":"2744_CR49","doi-asserted-by":"publisher","first-page":"516","DOI":"10.1016\/s2213-8587(25)00064-6","volume":"13","author":"S Leboulleux","year":"2025","unstructured":"Leboulleux S, et al. Redifferentiation therapy in unresectable or metastatic radioactive iodine refractory thyroid cancer: an International Thyroid Oncology Group statement. Lancet Diabetes Endocrinol. 2025;13:516\u201327. https:\/\/doi.org\/10.1016\/s2213-8587(25)00064-6.","journal-title":"Lancet Diabetes Endocrinol"},{"key":"2744_CR50","doi-asserted-by":"publisher","first-page":"1639","DOI":"10.1158\/1078-0432.Ccr-14-2339","volume":"21","author":"L Liu","year":"2015","unstructured":"Liu L, et al. The BRAF and MEK inhibitors dabrafenib and trametinib: effects on immune function and in combination with immunomodulatory antibodies targeting PD-1, PD-L1, and CTLA-4. Clin Cancer Res. 2015;21:1639\u201351. https:\/\/doi.org\/10.1158\/1078-0432.Ccr-14-2339.","journal-title":"Clin Cancer Res"},{"key":"2744_CR51","doi-asserted-by":"publisher","first-page":"393","DOI":"10.1158\/1078-0432.Ccr-12-1626","volume":"19","author":"C Liu","year":"2013","unstructured":"Liu C, et al. BRAF inhibition increases tumor infiltration by T cells and enhances the antitumor activity of adoptive immunotherapy in mice. Clin Cancer Res. 2013;19:393\u2013403. https:\/\/doi.org\/10.1158\/1078-0432.Ccr-12-1626.","journal-title":"Clin Cancer Res"},{"key":"2744_CR52","doi-asserted-by":"publisher","first-page":"53","DOI":"10.1038\/s41590-020-00818-9","volume":"22","author":"V Verma","year":"2021","unstructured":"Verma V, et al. MEK inhibition reprograms CD8(+) T lymphocytes into memory stem cells with potent antitumor effects. Nat Immunol. 2021;22:53\u201366. https:\/\/doi.org\/10.1038\/s41590-020-00818-9.","journal-title":"Nat Immunol"},{"key":"2744_CR53","doi-asserted-by":"publisher","unstructured":"Mitra, T. et al. MEK-dependent bioenergetic demand drives terminal CD8+ T cell exhaustion. bioRxiv, 2025.2004.2030.651453 (2025). https:\/\/doi.org\/10.1101\/2025.04.30.651453","DOI":"10.1101\/2025.04.30.651453"},{"key":"2744_CR54","doi-asserted-by":"publisher","first-page":"12","DOI":"10.1097\/CJI.0000000000000061","volume":"38","author":"T Gargett","year":"2015","unstructured":"Gargett T, Fraser CK, Dotti G, Yvon ES, Brown MP. BRAF and MEK inhibition variably affect GD2-specific chimeric antigen receptor (CAR) T-cell function in vitro. J Immunother. 2015;38:12\u201323. https:\/\/doi.org\/10.1097\/CJI.0000000000000061.","journal-title":"J Immunother"},{"key":"2744_CR55","doi-asserted-by":"publisher","first-page":"4026","DOI":"10.1111\/cas.15074","volume":"112","author":"A Tomida","year":"2021","unstructured":"Tomida A, et al. Inhibition of MEK pathway enhances the antitumor efficacy of chimeric antigen receptor T cells against neuroblastoma. Cancer Sci. 2021;112:4026\u201336. https:\/\/doi.org\/10.1111\/cas.15074.","journal-title":"Cancer Sci"},{"key":"2744_CR56","doi-asserted-by":"publisher","DOI":"10.3390\/ijms19010289","author":"J D\u00f6rrie","year":"2018","unstructured":"D\u00f6rrie J, et al. BRAF and MEK inhibitors influence the function of reprogrammed T cells: consequences for adoptive T-cell therapy. Int J Mol Sci. 2018. https:\/\/doi.org\/10.3390\/ijms19010289.","journal-title":"Int J Mol Sci"},{"key":"2744_CR57","doi-asserted-by":"publisher","DOI":"10.1038\/s41392-024-01986-y","volume":"9","author":"X Wang","year":"2024","unstructured":"Wang X, et al. MEK inhibition prevents CAR-T cell exhaustion and differentiation via downregulation of c-Fos and JunB. Signal Transduct Target Ther. 2024;9:293. https:\/\/doi.org\/10.1038\/s41392-024-01986-y.","journal-title":"Signal Transduct Target Ther"},{"key":"2744_CR58","doi-asserted-by":"publisher","unstructured":"Amirmahani, F., Kumar, S. & Muthukrishnan, S. D. Epigenetic mechanisms of plasticity and resistance in glioblastoma: therapeutic targets and implications. Frontiers in Epigenetics and Epigenomics Volume 3 - 2025 (2025). https:\/\/doi.org\/10.3389\/freae.2025.1519449","DOI":"10.3389\/freae.2025.1519449"},{"key":"2744_CR59","doi-asserted-by":"publisher","first-page":"166","DOI":"10.1016\/j.cell.2023.11.037","volume":"187","author":"J Pozniak","year":"2024","unstructured":"Pozniak J, et al. A TCF4-dependent gene regulatory network confers resistance to immunotherapy in melanoma. Cell. 2024;187:166-183.e125. https:\/\/doi.org\/10.1016\/j.cell.2023.11.037.","journal-title":"Cell"},{"key":"2744_CR60","doi-asserted-by":"publisher","first-page":"1063","DOI":"10.1038\/s43018-023-00595-y","volume":"4","author":"A P\u00e9rez-Gonz\u00e1lez","year":"2023","unstructured":"P\u00e9rez-Gonz\u00e1lez A, B\u00e9vant K, Blanpain C. Cancer cell plasticity during tumor progression, metastasis and response to therapy. Nat Cancer. 2023;4:1063\u201382. https:\/\/doi.org\/10.1038\/s43018-023-00595-y.","journal-title":"Nat Cancer"},{"key":"2744_CR61","doi-asserted-by":"publisher","first-page":"257","DOI":"10.1007\/978-981-95-3628-3_10","volume-title":"Advancement in CAR T-cell therapy in tumors: current challenges and future directions","author":"K Umadevi","year":"2026","unstructured":"Umadevi K, Sundeep D, Kumar U, Pal D, Parashar D. In advancement in CAR T-cell therapy in tumors: current challenges and future directions. In: Kumar U, Kumar A, Parashar D, editors. Advancement in CAR T-cell therapy in tumors: current challenges and future directions. Springer Nature Singapore; 2026. p. 257\u201395."},{"key":"2744_CR62","doi-asserted-by":"publisher","first-page":"878","DOI":"10.1111\/cen.14681","volume":"96","author":"J Furmaniak","year":"2022","unstructured":"Furmaniak J, Sanders J, Sanders P, Li Y, Rees Smith B. TSH receptor specific monoclonal autoantibody K1-70TM targeting of the TSH receptor in subjects with Graves\u2019 disease and Graves\u2019 orbitopathy\u2014results from a phase I clinical trial. Clin Endocrinol (Oxf). 2022;96:878\u201387. https:\/\/doi.org\/10.1111\/cen.14681.","journal-title":"Clin Endocrinol (Oxf)"},{"key":"2744_CR63","doi-asserted-by":"publisher","DOI":"10.1089\/thy.2021.0053","author":"M Ryder","year":"2021","unstructured":"Ryder M, et al. Blocking the thyrotropin receptor with K1-70 in a patient with follicular thyroid cancer, Graves\u2019 disease, and Graves\u2019 ophthalmopathy. Thyroid. 2021. https:\/\/doi.org\/10.1089\/thy.2021.0053.","journal-title":"Thyroid"},{"key":"2744_CR64","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2021.39.15_suppl.e14507","author":"L Xiao","year":"2021","unstructured":"Xiao L, et al. CoupledCAR technology for treating thyroid cancer. J Clin Oncol. 2021. https:\/\/doi.org\/10.1200\/JCO.2021.39.15_suppl.e14507.","journal-title":"J Clin Oncol"},{"key":"2744_CR65","doi-asserted-by":"publisher","DOI":"10.1186\/s40164-022-00311-z","volume":"11","author":"J Ding","year":"2022","unstructured":"Ding J, et al. Chimeric antigen receptor T-cell therapy for relapsed and refractory thyroid cancer. Exp Hematol Oncol. 2022;11:59. https:\/\/doi.org\/10.1186\/s40164-022-00311-z.","journal-title":"Exp Hematol Oncol"}],"container-title":["Molecular Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12943-026-02744-0","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12943-026-02744-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12943-026-02744-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,17]],"date-time":"2026-09-17T03:09:12Z","timestamp":1789614552000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s12943-026-02744-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,31]]},"references-count":65,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["2744"],"URL":"https:\/\/doi.org\/10.1186\/s12943-026-02744-0","relation":{},"ISSN":["1476-4598"],"issn-type":[{"value":"1476-4598","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,7,31]]},"assertion":[{"value":"1 May 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 July 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"31 July 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The use of recombinant DNA in the laboratory was approved by the Mayo Clinic Institutional Biosafety Committee (IBC), IBC number HIP00001516.06. Animal studies were performed according to the Institutional Animal Care and Use Committee (IACUC) at the Mayo Clinic animal facilities (IACUC # A00001767), including adherence to tumor burden guidelines of tumors no greater than 10% of mouse body weight.","order":1,"name":"Ethics","label":"Ethics approval and consent to participate","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"All authors have reviewed and approved the final version of the manuscript for publication.","order":2,"name":"Ethics","label":"Consent for publication","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"SSK is an inventor on patents in the field of CAR immunotherapy that are licensed to Novartis (through an agreement between Mayo Clinic, University of Pennsylvania, and Novartis). SSK and RLS are inventors on patents that are licensed to Humanigen\/Taran (through Mayo Clinic). SSK is an inventor on patents that are licensed to MustangBio (through Mayo Clinic). ELS, EET, RLS, OLS, KJS, and SSK are inventors on patents that are licensed to Chymal (through Mayo Clinic). CMR, ELS, TNH, LKM, BLK, RLS, CMS, IC, OLS, JMF, KY, OGR, HX, MHT, JAC and SSK are inventors on patents licensed to Immix (through Mayo Clinic). SSK receives research funding from Kite, Gilead, Juno, BMS, Novartis, Humanigen\/Taran, MorphoSys, Tolero, Sunesis\/Viracta, LifEngine Animal Health Laboratories Inc, and Lentigen. SSK has participated in advisory meetings with Kite\/Gilead, Calibr, Luminary Therapeutics, Humanigen, Juno\/BMS, Capstan Bio, Carisma, and Novartis. SSK has served on the data safety and monitoring board with Humanigen. SSK has served as a consultant for Torque, Calibr, Novartis, Capstan Bio, Carisma Therapeutics, JW Therapeutics, and Humanigen.","order":3,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Declarations"}}],"article-number":"219"}}